Table 4.
Duration of Postmenopausal Hormone Therapy and Risk of Hearing Loss Among Postmenopausal Women, Nurses’ Health Study II (1991-2013)
| Duration of Oral HT Use |
Cases | Person-years | Age-adjusted RR (95% CI) |
Multivariable- adjusted RRa (95% CI) |
|---|---|---|---|---|
| Never | 3267 | 149,062 | 1.00 (ref) | 1.00 (ref) |
| Ever Oral HT | ||||
| <1 yr | 388 | 19,214 | 1.12 (1.00, 1.24) | 1.09 (0.98, 1.21) |
| 1–1.9 yrs | 544 | 27,465 | 1.13 (1.03, 1.24) | 1.10 (1.00, 1.21) |
| 2-4.9 yrs | 1064 | 49,993 | 1.10 (1.02, 1.18) | 1.08 (1.00, 1.16) |
| 5-9.9 yrs | 1018 | 40,488 | 1.14 (1.06, 1.23) | 1.15 (1.06, 1.24) |
| 10+ yrs | 399 | 12,983 | 1.20 (1.08, 1.34) | 1.21 (1.07, 1.37) |
| p-trend | <0.001 | <0.001 |
a
Multivariable models adjusted for age; race; body mass index; waist circumference; physical activity; smoking; hypertension; diabetes; intake of alcohol, folate, vitamin B12, vitamin C, magnesium, long chain omega-3 fatty acids, trans-fat, beta-carotene and beta-cryptoxanthin; ibuprofen use; acetaminophen use; tinnitus; parity; use of non-oral HT; type of menopause; and age at menopause.
HT, hormone therapy